Diffuse cutaneous leishmaniasis acquired in Peru.
A case of diffuse cutaneous leishmaniasis (DCL) acquired in Peru is described. The causative agent was Leishmania mexicana amazonensis as determined by isoenzyme analysis and species-specific monoclonal antibody binding characteristics. Histological examination of biopsy material showed a large number of intracellular and extracellular amastigotes and few lymphocytes. Treatment with meglumine antimoniate (Glucantime) administered iv at a dosage of 20 mg antimony/kg body weight/day for 60 days resulted in visible improvement of the lesions, but not in clinical or parasitological cure.
Franke
E D
ED
U.S. Naval Medical Research Institute Detachment-Lima, APO Miami, FL 34031.
Lucas
C M
CM
Tovar
A A
AA
Kruger
J H
JH
De Rivera
M V
MV
Wignall
F S
FS
D000328:Adult; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001706:Biopsy; D005260:Female; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D010568:Peru / Q000453:epidemiology; D012867:Skin / Q000473:pathology
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony